- Trial phase
- Approved
- Time to market
- Already approved and marketed since 2012.
- Why 3/10
- Elelyso is an approved, marketed drug that Protalix sold its entire economic interest in to Pfizer in 2015. It generates no revenue for PLX and has no scheduled catalysts tied to the company. The stock's next binary catalyst is the PRX-115 Phase 2 topline readout expected in H2 2027, not Elelyso.
Elelyso is not a Protalix revenue driver and has no upcoming catalysts tied to PLX. Investors should focus on Protalix's current commercial product Elfabrio (partnered with Chiesi) and the Phase 2 PRX-115 readout expected in H2 2027 for the stock's next binary catalyst.
Price Chart
Executive Summary
Elelyso (taliglucerase alfa) is an enzyme replacement therapy for Type 1 Gaucher disease that the FDA approved in May 2012. It was developed by Protalix BioTherapeutics (PLX) using its plant-cell ProCellEx platform and originally commercialized with Pfizer. In October 2015, Protalix sold its entire 40% collaboration stake in Elelyso to Pfizer, which now fully owns and markets the drug. Elelyso generates no revenue for Protalix and is a legacy asset with no bearing on the company's current value proposition, which centers on Elfabrio (for Fabry disease) and the Phase 2 pipeline asset PRX-115 (for uncontrolled gout).
How It Works
Elelyso is an enzyme replacement therapy (ERT) that replaces the missing or deficient enzyme (glucocerebrosidase) in people with Type 1 Gaucher disease, a rare genetic disorder. It is produced using genetically engineered plant cells (carrot cells), a unique manufacturing platform called ProCellEx.
Trial Status
Elelyso was FDA-approved on May 1, 2012 for Type 1 Gaucher disease. It has also received approvals in Australia, Israel, and other markets. It is a commercially marketed product, now fully owned by Pfizer after Protalix sold its collaboration stake in October 2015.
The Two-Sided Case
Upcoming Catalysts
- None for Elelyso specifically. For PLX broadly: PRX-115 Phase 2 topline data expected H2 2027.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Protalix BioTherapeutics, Inc. 8-K PLX ·Originating report